Approvals/TGA/AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial for suspension for injection

Approved

STANDARD

AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial for suspension for injection

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: cb030bcdfa0b87ba
Company: GlaxoSmithKline Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: cb030bcdfa0b87ba
Product Name: AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial for suspension for injection
Artg Id: 400657
Artg Name: AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension vial suspension for injection
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2024-01-14
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/aff00798411a8d6e525d064724e59cdd.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/727798f2ca90ddf730cbf8b974852c98.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

cb030bcdfa0b87ba

Type

Standard

Back to TGA Approvals